Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)

Background: Agents targeting angiogenesis or PD-L1/PD-1 signalling represent 2 types of approved treatments (tx) for HCC. In addition to its anti-angiogenic activity, bevacizumab (bev; anti-VEGF) has immunomodulatory effects that alter the tumour microenvironment, which may augment atezolizumab (atezo; anti–PD-L1)-mediated anti-tumour immune responses. This scientific rationale, including preclinical and clinical data, supports the hypothesis...